| Primary |
| Burkitt's Lymphoma |
60.7% |
| Extravasation |
14.3% |
| Prophylaxis |
8.9% |
| Acute Myeloid Leukaemia |
7.1% |
| Immunosuppression |
5.4% |
| Nausea |
3.6% |
|
| Renal Impairment |
18.8% |
| Skin Graft |
12.5% |
| Burning Sensation |
6.3% |
| Drug Ineffective |
6.3% |
| Extravasation |
6.3% |
| Necrosis |
6.3% |
| Neoplasm Malignant |
6.3% |
| Neutropenia |
6.3% |
| Retinoic Acid Syndrome |
6.3% |
| Surgery |
6.3% |
| Tic |
6.3% |
| Treatment Related Secondary Malignancy |
6.3% |
| Vomiting |
6.3% |
|
| Secondary |
| Burkitt's Lymphoma |
26.6% |
| Prophylaxis |
14.6% |
| Drug Use For Unknown Indication |
13.4% |
| Product Used For Unknown Indication |
8.7% |
| Chemotherapy |
6.4% |
| Osteosarcoma Metastatic |
4.2% |
| Acute Lymphocytic Leukaemia |
3.3% |
| Immunosuppression |
3.3% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
2.7% |
| Extravasation |
2.5% |
| Hodgkin's Disease |
2.5% |
| Ill-defined Disorder |
2.5% |
| Heart Transplant |
1.7% |
| Sarcoma |
1.4% |
| Breast Cancer |
1.3% |
| Neuroblastoma |
1.1% |
| B-cell Lymphoma |
1.0% |
| Bone Sarcoma |
1.0% |
| Diffuse Large B-cell Lymphoma |
1.0% |
| Acute Myeloid Leukaemia |
0.9% |
|
| Renal Impairment |
24.0% |
| Renal Failure Acute |
15.6% |
| Off Label Use |
12.5% |
| Febrile Neutropenia |
8.3% |
| Tic |
6.3% |
| Hyperbilirubinaemia |
5.2% |
| Neutropenia |
4.2% |
| Staphylococcal Bacteraemia |
3.1% |
| Vomiting |
3.1% |
| Generalised Erythema |
2.1% |
| Guillain-barre Syndrome |
2.1% |
| Lymphocyte Count Decreased |
2.1% |
| Neoplasm Malignant |
2.1% |
| Weight Decreased |
2.1% |
| White Blood Cell Count Decreased |
2.1% |
| Acute Myelomonocytic Leukaemia |
1.0% |
| Aspartate Aminotransferase Increased |
1.0% |
| Lymphoproliferative Disorder |
1.0% |
| Malnutrition |
1.0% |
| Myeloid Leukaemia |
1.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
45.2% |
| Breast Cancer |
15.9% |
| Product Used For Unknown Indication |
9.3% |
| Chemotherapy |
5.8% |
| Osteosarcoma Metastatic |
4.9% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Endometrial Cancer |
2.2% |
| Hiv Infection |
2.2% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| Hodgkin's Disease |
1.4% |
| Cardiomyopathy |
1.1% |
| Immunosuppression |
1.1% |
| Inflammatory Myofibroblastic Tumour |
1.1% |
| Neoplasm |
1.1% |
| Acute Leukaemia |
0.8% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
0.8% |
| Heart Transplant |
0.8% |
| Prophylaxis |
0.8% |
| Blood Triglycerides Increased |
0.5% |
| Bone Sarcoma |
0.5% |
|
| Left Ventricular Dysfunction |
18.9% |
| Localised Infection |
8.1% |
| Neutropenia |
8.1% |
| Pulmonary Hypertension |
8.1% |
| Pyrexia |
8.1% |
| Cardiotoxicity |
5.4% |
| Febrile Neutropenia |
5.4% |
| Urinary Tract Infection |
5.4% |
| Burkitt's Leukaemia |
2.7% |
| Cardiac Failure |
2.7% |
| Cholestasis |
2.7% |
| Disease Progression |
2.7% |
| Drug Ineffective |
2.7% |
| Dyspnoea |
2.7% |
| Febrile Bone Marrow Aplasia |
2.7% |
| Flushing |
2.7% |
| Hypothyroidism |
2.7% |
| Influenza Like Illness |
2.7% |
| Monoplegia |
2.7% |
| Pain In Jaw |
2.7% |
|
